205 related articles for article (PubMed ID: 31397525)
41. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
[TBL] [Abstract][Full Text] [Related]
42. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
43. PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions.
Tan X; Xu L; Jian X; Ouyang J; Hu B; Yang X; Wang T; Xie L
Cells; 2023 Mar; 12(5):. PubMed ID: 36899918
[TBL] [Abstract][Full Text] [Related]
44. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
45. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
46. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
Lennerz V; Fatho M; Gentilini C; Frye RA; Lifke A; Ferel D; Wölfel C; Huber C; Wölfel T
Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16013-8. PubMed ID: 16247014
[TBL] [Abstract][Full Text] [Related]
47. Improvement of Neoantigen Identification Through Convolution Neural Network.
Hao Q; Wei P; Shu Y; Zhang YG; Xu H; Zhao JN
Front Immunol; 2021; 12():682103. PubMed ID: 34113354
[TBL] [Abstract][Full Text] [Related]
48. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
49. Neoantigens encoded in the cancer genome.
Schumacher TN; Hacohen N
Curr Opin Immunol; 2016 Aug; 41():98-103. PubMed ID: 27518850
[TBL] [Abstract][Full Text] [Related]
50. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
51. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis.
Wen B; Li K; Zhang Y; Zhang B
Nat Commun; 2020 Apr; 11(1):1759. PubMed ID: 32273506
[TBL] [Abstract][Full Text] [Related]
52. Tumor-specific shared antigenic peptides recognized by human T cells.
Van Der Bruggen P; Zhang Y; Chaux P; Stroobant V; Panichelli C; Schultz ES; Chapiro J; Van Den Eynde BJ; Brasseur F; Boon T
Immunol Rev; 2002 Oct; 188():51-64. PubMed ID: 12445281
[TBL] [Abstract][Full Text] [Related]
53. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.
Koster J; Plasterk RHA
Sci Rep; 2019 Apr; 9(1):6577. PubMed ID: 31036835
[TBL] [Abstract][Full Text] [Related]
54. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S; Wolf Y; Feferman T; Barnea E; Greenstein E; Reshef D; Tirosh I; Reuben A; Patkar S; Levy R; Quinkhardt J; Omokoko T; Qutob N; Golani O; Zhang J; Mao X; Song X; Bernatchez C; Haymaker C; Forget MA; Creasy C; Greenberg P; Carter BW; Cooper ZA; Rosenberg SA; Lotem M; Sahin U; Shakhar G; Ruppin E; Wargo JA; Friedman N; Admon A; Samuels Y
Cancer Discov; 2018 Nov; 8(11):1366-1375. PubMed ID: 30209080
[TBL] [Abstract][Full Text] [Related]
55. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
56. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
57. TANTIGEN: a comprehensive database of tumor T cell antigens.
Olsen LR; Tongchusak S; Lin H; Reinherz EL; Brusic V; Zhang GL
Cancer Immunol Immunother; 2017 Jun; 66(6):731-735. PubMed ID: 28280852
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy: natural versus synthetic peptides.
Protti MP; Bellone M
Immunol Today; 1998 Feb; 19(2):98. PubMed ID: 9509766
[No Abstract] [Full Text] [Related]
59. BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens.
Cuevas MVR; Hardy MP; Larouche JD; Apavaloaei A; Kina E; Vincent K; Gendron P; Laverdure JP; Durette C; Thibault P; Lemieux S; Perreault C; Ehx G
Genome Biol; 2023 Aug; 24(1):188. PubMed ID: 37582761
[TBL] [Abstract][Full Text] [Related]
60. The human leukocyte antigen-presented ligandome of B lymphocytes.
Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
